Search Results - "JAKUBIAK, Diana"

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP by Zhou, Yi, Fei, Mingjian, Zhang, Gu, Liang, Wei-Ching, Lin, WeiYu, Wu, Yan, Piskol, Robert, Ridgway, John, McNamara, Erin, Huang, Haochu, Zhang, Juan, Oh, Jaehak, Patel, Jaina M., Jakubiak, Diana, Lau, Jeff, Blackwood, Beth, Bravo, Daniel D., Shi, Yongchang, Wang, Jianyong, Hu, Hong-Ming, Lee, Wyne P., Jesudason, Rajiv, Sangaraju, Dewakar, Modrusan, Zora, Anderson, Keith R., Warming, Søren, Roose-Girma, Merone, Yan, Minhong

“…Clearance of apoptotic cells by macrophages prevents excessive inflammation and supports immune tolerance. Here, we examined the effect of blocking apoptotic…”
Get full text

Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window by Rudolph, Joachim, Murray, Lesley J, Ndubaku, Chudi O, O’Brien, Thomas, Blackwood, Elizabeth, Wang, Weiru, Aliagas, Ignacio, Gazzard, Lewis, Crawford, James J, Drobnick, Joy, Lee, Wendy, Zhao, Xianrui, Hoeflich, Klaus P, Favor, David A, Dong, Ping, Zhang, Haiming, Heise, Christopher E, Oh, Angela, Ong, Christy C, La, Hank, Chakravarty, Paroma, Chan, Connie, Jakubiak, Diana, Epler, Jennifer, Ramaswamy, Sreemathy, Vega, Roxanne, Cain, Gary, Diaz, Dolores, Zhong, Yu

“…p21-activated kinase 1 (PAK1) has an important role in transducing signals in several oncogenic pathways. The concept of inhibiting this kinase has garnered…”
Get full text

P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma by ONG, Christy C, JUBB, Adrian M, HARRIS, Adrian L, FRIEDMAN, Lori S, BELVIN, Marcia, MIDDLETON, Mark R, BLACKWOOD, Elizabeth M, KOEPPEN, Hartmut, HOEFLICH, Klaus P, JAKUBIAK, Diana, WEI ZHOU, RUDOLPH, Joachim, HAVERTY, Peter M, KOWANETZ, Marcin, YIBING YAN, TREMAYNE, Jarrod, LISLE, Richard

“…Although remarkable clinical response rates in melanoma have been observed using vemurafenib or dabrafenib in patients with tumors carrying oncogenic mutations…”
Get full text

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pKa Polar Moiety by Ndubaku, Chudi O., Crawford, James J., Drobnick, Joy, Aliagas, Ignacio, Campbell, David, Dong, Ping, Dornan, Laura M., Duron, Sergio, Epler, Jennifer, Gazzard, Lewis, Heise, Christopher E., Hoeflich, Klaus P., Jakubiak, Diana, La, Hank, Lee, Wendy, Lin, Baiwei, Lyssikatos, Joseph P., Maksimoska, Jasna, Marmorstein, Ronen, Murray, Lesley J., O’Brien, Thomas, Oh, Angela, Ramaswamy, Sreemathy, Wang, Weiru, Zhao, Xianrui, Zhong, Yu, Blackwood, Elizabeth, Rudolph, Joachim

“…Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the…”
Get full text

Design of Selective PAK1 Inhibitor G‑5555: Improving Properties by Employing an Unorthodox Low‑pK a Polar Moiety by Ndubaku, Chudi O, Crawford, James J, Drobnick, Joy, Aliagas, Ignacio, Campbell, David, Dong, Ping, Dornan, Laura M, Duron, Sergio, Epler, Jennifer, Gazzard, Lewis, Heise, Christopher E, Hoeflich, Klaus P, Jakubiak, Diana, La, Hank, Lee, Wendy, Lin, Baiwei, Lyssikatos, Joseph P, Maksimoska, Jasna, Marmorstein, Ronen, Murray, Lesley J, O’Brien, Thomas, Oh, Angela, Ramaswamy, Sreemathy, Wang, Weiru, Zhao, Xianrui, Zhong, Yu, Blackwood, Elizabeth, Rudolph, Joachim

“…Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the…”
Get full text

Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900 by Blackwood, Elizabeth, Epler, Jennifer, Yen, Ivana, Flagella, Michael, O'Brien, Tom, Evangelista, Marie, Schmidt, Stephen, Xiao, Yang, Choi, Jonathan, Kowanetz, Kaska, Ramiscal, Judi, Wong, Kenton, Jakubiak, Diana, Yee, Sharon, Cain, Gary, Gazzard, Lewis, Williams, Karen, Halladay, Jason, Jackson, Peter K, Malek, Shiva

“…Checkpoint kinase 1 (ChK1) is a serine/threonine kinase that functions as a central mediator of the intra-S and G2-M cell-cycle checkpoints. Following DNA…”
Get full text

Abstract 944: Development of predictive and pharmacodynamic biomarker strategies for GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine by Mahrus, Sami, DuPree, Kelly, Kowanetz, Kaska, Tan, Jenille, Tremayne, Jarrod, Jakubiak, Diana, Haverty, Peter, Zhu, Yuda, Peale, Franklin, Blackwood, Elizabeth, Bourgon, Richard, Yauch, Robert, Lackner, Mark, Evangelista, Marie

“…Abstract GDC-0425 is a potent and selective small molecule inhibitor of checkpoint kinase 1 (Chk1) recently evaluated in the DPM4957g phase I study in…”
Get full text

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-p K a Polar Moiety by Ndubaku, Chudi O., Crawford, James J., Drobnick, Joy, Aliagas, Ignacio, Campbell, David, Dong, Ping, Dornan, Laura M., Duron, Sergio, Epler, Jennifer, Gazzard, Lewis, Heise, Christopher E., Hoeflich, Klaus P., Jakubiak, Diana, La, Hank, Lee, Wendy, Lin, Baiwei, Lyssikatos, Joseph P., Maksimoska, Jasna, Marmorstein, Ronen, Murray, Lesley J., O’Brien, Thomas, Oh, Angela, Ramaswamy, Sreemathy, Wang, Weiru, Zhao, Xianrui, Zhong, Yu, Blackwood, Elizabeth, Rudolph, Joachim

Get full text